论文部分内容阅读
目的观察125I粒子植入联合化疗治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效和安全性。方法Ⅲ期NSCLC患者31例,均于植入125I粒子行组织间放疗后给予GP(吉西他滨+顺铂)化疗方案2～4个周期,治疗2、6个月复查CT评定疗效,观察患者生存期并计算照射剂量。结果治疗后2个月复查CT,完全缓解1例,部分缓解28例,无变化2例;6个月复查CT,完全缓解18例,部分缓解9例,进展4例;随访存活1a以上15例,2a以上10例,3a以上6例,其中1例无瘤生存7a;肿瘤实际受照最小周边剂量80～150Gy,90%肿瘤区实际最小周边计量110～145Gy,1例距心包最近肿瘤外1cm处,心包剂量为22.4Gy;1例距脊髓最近肿瘤外2cm处,脊髓剂量为6.3Gy。结论 125I粒子植入治疗NSCLC安全、可靠,并发症可控,放疗剂量分布可合理控制。
Objective To observe the efficacy and safety of 125I seed implantation and chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Methods Totally 31 patients with stage Ⅲ NSCLC were treated with GPI (gemcitabine plus cisplatin) chemotherapy for 2 to 4 cycles after intraluminal 125I seed implantation. The therapeutic effect of CT was evaluated after 2 and 6 months of treatment. The survival of the patients was observed. And calculate the irradiation dose. Results Two months after the treatment, the CT was reviewed. One case was completely relieved, the other 28 cases were partially relieved. There was no change in 2 cases. Six months after CT, 18 cases were completely relieved, 9 cases partially relieved and 4 cases progressed. Survival was more than 1a in 15 cases , More than 2a in 10 cases, more than 3a in 6 cases, 1 case of tumor-free survival 7a; the actual exposure to the tumor peripheral minimum dose of 80 ~ 150Gy, 90% of the actual measurement of peripheral tumor area 110 ~ 145Gy, 1 cases away from the nearest pericardial tumor 1cm Department, the pericardial dose of 22.4Gy; 1 case 2cm away from the nearest tumor of the spinal cord, spinal dose of 6.3Gy. Conclusion The 125I particle implantation is safe and reliable in the treatment of NSCLC. The complications can be controlled and the dose distribution of radiotherapy can be reasonably controlled.